The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...

The following is a summary of “Vancomycin-resistant Enterococcus (VRE) Pneumonia in a Patient With Advanced Chronic ...

What level of billing is an exacerbation of COPD in patient with diabetes; treated with corticosteroids, oxygen; insulin ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among ...

Denham Thomas, from Hartlepool, saw his life drastically altered by Chronic Obstructive Pulmonary Disease, becoming dependent ...